Novel treatments for diastolic heart failure

Udi Nussinovitch, Guy Topaz, Amir Landesberg, Yair Feld

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Diastolic heart failure (DHF) is caused by inadequate dilatation of the left ventricle during diastole, while the ejection fraction may be preserved or reduced. It is estimated that 40%-50% of patients with heart failure present with DHF. These patients are characterized by high mortality rates and frequent hospitalizations, similar to those found in patients with systolic heart failure. Currently available medical treatment includes modification of risk factors such as blood pressure control and pharmacotherapy. Despite these therapies, the overall prognosis of DHF remains poor. This chapter reviews current methods and novel approaches for treating patients with DHF.

Original languageEnglish
Title of host publicationEmerging Technologies for Heart Diseases
Subtitle of host publicationVolume 1: Treatments for Heart Failure and Valvular Disorders
PublisherElsevier
Pages95-127
Number of pages33
ISBN (Electronic)9780128137062
DOIs
StatePublished - 1 Jan 2020

Keywords

  • Diastolic dysfunction
  • Heart failure
  • Passive diastolic assistive device
  • Reduced ejection fraction

Fingerprint

Dive into the research topics of 'Novel treatments for diastolic heart failure'. Together they form a unique fingerprint.

Cite this